2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-173288
    MAO-B-IN-40 2486914-15-0 98%
    MAO-B-IN-40 (3a), a MAOB inhibitor (IC50 = 0.493 μM for hMAOB), demonstrates robust neuroprotective and antioxidant effect. MAO-B-IN-40 (3a) can be used in the research of Parkinson’s disease.
    MAO-B-IN-40
  • HY-173291
    Tau ligand-1 3063166-64-0 98%
    Tau ligand-1 (Compound 75) is a ligand for aggregated tau protein that can penetrate the blood-brain barrier. In tissues from patients with Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and Pick's disease, Tau ligand-1 exhibits high affinity for aggregated tau protein, with equilibrium dissociation constant (KD) values ranging from 1 to 3.8 nM. Tau ligand-1 can serve as a potential positron emission tomography (PET) tracer and holds promise for application in positron emission tomography imaging studies of tau-related diseases in the central nervous system.
    Tau ligand-1
  • HY-173294
    NLRP3-IN-74 98%
    NLRP3-IN-74 (Compound 11) is an orally active NLRP3 inhibitor with an IC50 value of 2.7 μM. NLRP3-IN-74 can inhibit the release of IL-1β, reducing the release level by approximately 90%, and does not inhibit the release of TNFα. NLRP3-IN-74 can be used in the research of related diseases such as atherosclerosis and Parkinson's disease.
    NLRP3-IN-74
  • HY-173334
    hMAO-B-IN-11 98%
    hMAO-B-IN-11 (Compound 12) is a selective and reversible inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 of 0.11 µM. hMAO-B-IN-11 acts through competitive binding to the hMAO-B active site, preventing oxidative deamination of monoamines and reducing hydrogen peroxide production. hMAO-B-IN-11 also inhibits pro-inflammatory mediators (NO, TNF-α, IL-1β) in activated microglia, hMAO-B-IN-11 is promising for research of neurodegenerative diseases like Parkinson’s and Alzheimer’s.
    hMAO-B-IN-11
  • HY-173336
    MAO-B-IN-42 2568016-10-2 98%
    MAO-B-IN-42 (Compound 4f) is a selective and reversible inhibitor of monoamine oxidase-B (MAO-B) with an IC50 value of 0.184 μM. MAO-B-IN-42 helps maintain the levels of neurotransmitters by blocking the oxidative deamination of monoamines catalyzed by MAO-B. MAO-B-IN-42 is promising for research of Parkinson's disease.
    MAO-B-IN-42
  • HY-173339
    VIP36 98%
    VIP36 is an agonist of cannabinoid receptor type 1 (CB1) and has analgesic activity. VIP36 exerts its analgesic activity by reducing the recruitment of arrestin proteins and can be used for research in the field of chronic pain.
    VIP36
  • HY-173344
    DB-10 98%
    DB-10 is a pro-agent of 3-nbutylphthalide (NBP) (HY-B0647). DB-10 has significantly high uptake ability via pyrilamine cationic transporters in the temperature and energy dependent manner in cells. DB-10 improves the survival rate of cells. DB-10 could rapidly convert into active original agent and increase the accumulation in the brain in vivo. DB-10 can be used for ischemic stroke study.
    DB-10
  • HY-173347
    BLINK11 98%
    BLINK11 is a BBB-penetrant CDK5 inhibitor. BLINK11 lowers CDK5 activity for both complexes CDK5/p35 (IC50 = 17.09 nM) and CDK5/p25 (IC50 = 14.69 nM). BLINK11 offers anti-diabetic and neuroprotective benefits. BLINK11 lowers blood glucose, enhances cognition, and reduces neurodegeneration in T2D mice.
    BLINK11
  • HY-173348
    BLINK15 98%
    BLINK15 is a BBB-penetrant CDK5 inhibitor. BLINK15 lowers CDK5 activity for both complexes CDK5/p35 (IC50 = 29.34 nM) and CDK5/p25 (IC50 = 12.08 nM). BLINK15 offers anti-diabetic and neuroprotective benefits. BLINK15 lowers blood glucose, enhances cognition, and reduces neurodegeneration in T2D mice.
    BLINK15
  • HY-173353
    ATXN1-MED15 PPI-IN-1 420106-23-6 98%
    ATXN1-MED15 PPI-IN-1 (compound 5755483) is an inhibitor of ATXN1/MED15. ATXN1-MED15 PPI-IN-1 binds to ATXN1 residues 99-163 and inhibits both the interaction between ATXN1 and MED15, as well as the dimerization of polyQ-expanded ATXN1. ATXN1-MED15 PPI-IN-1 can be used for study of Spinocerebellar ataxia type 1.
    ATXN1-MED15 PPI-IN-1
  • HY-173366
    dGEM3 98%
    dGEM3 is a molecular glue degrader targeting GEMIN3 (a member of the survival of motor neuron complex). dGEM3 can be used in the research of diseases related to abnormal protein regulation, such as cancer and neurodegenerative diseases.
    dGEM3
  • HY-173384
    DSPE-DOTA sodium 98%
    DSPE-DOTA sodium (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt) is a chelating lipid used as a key contrast agent in magnetic resonance imaging (MRI). DSPE-DOTA sodium can be used for imaging detection of tumors, neurological and inflammatory diseases.
    DSPE-DOTA sodium
  • HY-173395
    MAO-B-IN-43 98%
    MAO-B-IN-43 (4) is a potent hMAO-B inhibitor and a weak GSK3β kinase inhibitor, with Ki values of 0.044 μM and 0.004 μM for hMAO-A and hMAO-B, respectively. MAO-B-IN-43 (4) can be used for the research of neurodegenerative disorder.
    MAO-B-IN-43
  • HY-173396
    VU0467319 1432438-14-6 98%
    VU0467319 (Compound VU319) is a highly selective and blood-brain-permeable, orally active M1 positive allosteric modulator (PAM) (EC50: 492 nM). VU0467319 is selective (EC50 > 30 μM) versus M2-5 for both human and rat. VU0467319 improves cognitive impairment in Alzheimer's disease (AD) through central M1 muscarinic receptors. VU0467319 does not induce cholinergic adverse reactions and has potential in AD research.
    VU0467319
  • HY-173398
    NMDAR antagonist 5 3038464-68-2 98%
    NMDAR antagonist 5 (Compound A17) is a multi-target antagonist against NMDAR and monoamine transporters (SERT、DAT and NET). NMDAR antagonist 5 shows good NMDAR antagonistic potency (IC50 = 0.3 μM) and monoamine transporter activities (SERT IC50 = 1.1 μM、DAT IC50 = 0.7 μM、NET IC50 = 2.7 μM). NMDAR antagonist 5 is highly safe and has low toxicity (hepatotoxicity and nephrotoxicity (IC50 > 100 μM); cardiotoxicity (IC50 = 24.5 μM)). NMDAR antagonist 5 has antidepressant effects and can be used in the study of depression.
    NMDAR antagonist 5
  • HY-173430
    AD015 177741-43-4 98%
    AD015 is a angiotensin-converting enzyme (ACE) and neprilysin (NEP) dual inhibitor. AD015 inhibits NEP, nACE and cACE with IC50s of 0.009, 0.019 and 0.0008 μM, respectively.
    AD015
  • HY-173449
    TRPM2-IN-1 2833727-43-6 98%
    TRPM2-IN-1 (compound D10) is a potent TRPM2 inhibitor. TRPM2-IN-1 exhibits antistroke activity and significant neuroprotective effect. TRPM2-IN-1 can be used in the study of ischemic stroke.
    TRPM2-IN-1
  • HY-173451
    TAAR1/5-H-2CR agonist-1 3024777-79-2 98%
    TAAR1/5-H-2CR agonist-1 (compound 21b) is a TAAR1 and 5-HT2CR dual agonist with EC50s of 0.022 and 0.246 μM, respectively. TAAR1/5-H-2CR agonist-1 can used in the study of schizophrenia and Alzheimer's Disease.
    TAAR1/5-H-2CR agonist-1
  • HY-173471
    TRPA1 agonist-1 98%
    TRPA1 agonist-1 (compound 21) is a potent and selective TAAR1 agonist with an EC50 of 25.47 μM. TRPA1 agonist-1 shows effective analgesic properties without irritation in mice.
    TRPA1 agonist-1
  • HY-173475
    CM699 1259949-84-2 98%
    CM699 is a potent Dopamine Transporter (DAT) and Sigma-receptor (σR) dual inhibitor with IC50s of 311 and 14.1 nM, respectively.
    CM699
Cat. No. Product Name / Synonyms Application Reactivity